Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer

PURPOSE: We examined the role of ERBB2 activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer. DESIGN: ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in ERBB2 mutations in ER+ MCF7 cells and xenografts were used to...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Croessmann, Sarah, Formisano, Luigi, Kinch, Lisa N., Gonzalez-Ericsson, Paula I., Sudhan, Dhivya R., Nagy, Rebecca J., Mathew, Aju, Bernicker, Eric H., Cristofanilli, Massimo, He, Jie, Cutler, Richard E., Lalani, Alshad S., Miller, Vincent A., Lanman, Richard B., Grishin, Nick V., Arteaga, Carlos L.
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6320312/
https://ncbi.nlm.nih.gov/pubmed/30314968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1544
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker